| Autor: |
Katharina S. Appel, Chin Huang Lee, Susana M. Nunes de Miranda, Daniel Maier, Jens-Peter Reese, Gabriele Anton, Thomas Bahmer, Sabrina Ballhausen, Beate Balzuweit, Carla Bellinghausen, Arne Blumentritt, Markus Brechtel, Irina Chaplinskaya-Sobol, Johanna Erber, Karin Fiedler, Ramsia Geisler, Ralf Heyder, Thomas Illig, Mirjam Kohls, Jenny Kollek, Lilian Krist, Roberto Lorbeer, Olga Miljukov, Lazar Mitrov, Carolin Nürnberger, Christian Pape, Christina Pley, Christian Schäfer, Jens Schaller, Mario Schattschneider, Margarete Scherer, Nick Schulze, Dana Stahl, Hans Christian Stubbe, Thalea Tamminga, Johannes Josef Tebbe, Maria J. G. T. Vehreschild, Silke Wiedmann, Jörg Janne Vehreschild |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2045-2322 |
| DOI: |
10.1038/s41598-024-63945-5 |
| Popis: |
Abstract Fair allocation of funding in multi-centre clinical studies is challenging. Models commonly used in Germany - the case fees (“fixed-rate model”, FRM) and up-front staffing and consumables (“up-front allocation model”, UFAM) lack transparency and fail to suitably accommodate variations in centre performance. We developed a performance-based reimbursement model (PBRM) with automated calculation of conducted activities and applied it to the cohorts of the National Pandemic Cohort Network (NAPKON) within the Network of University Medicine (NUM). The study protocol activities, which were derived from data management systems, underwent validation through standardized quality checks by multiple stakeholders. The PBRM output (first funding period) was compared among centres and cohorts, and the cost-efficiency of the models was evaluated. Cases per centre varied from one to 164. The mean case reimbursement differed among the cohorts (1173.21€ [95% CI 645.68–1700.73] to 3863.43€ [95% CI 1468.89–6257.96]) and centres and mostly fell short of the expected amount. Model comparisons revealed higher cost-efficiency of the PBRM compared to FRM and UFAM, especially for low recruitment outliers. In conclusion, we have developed a reimbursement model that is transparent, accurate, and flexible. In multi-centre collaborations where heterogeneity between centres is expected, a PBRM could be used as a model to address performance discrepancies. Trial registration: https://clinicaltrials.gov/ct2/show/NCT04768998 ; https://clinicaltrials.gov/ct2/show/NCT04747366 ; https://clinicaltrials.gov/ct2/show/NCT04679584 . |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
